Aquestive Therapeutics Inc Stock

$2.51-0.14 (-5.28%)
Updated Feb 21, 2024
AQST Price
Fair Value Price
Market Cap
52 Week Low
52 Week High
Dividend Yield
Gross Margin
Operating Margin
Profit Margin
Debt to Equity
Operating Cash Flow
Next Earnings
Mar 5, 2024
Next Dividend

AQST Overview

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.

Zen Score

Industry Average (24)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AQST scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AQST is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AQST is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
AQST's Earnings (EBIT) of -$6.04M... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more AQST due diligence checks available for Premium users.

Be the first to know about important AQST news, forecast changes, insider trades & much more!



AQST fair value

Fair Value of AQST stock based on Discounted Cash Flow (DCF)
Fair Value
Undervalued by
AQST is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

AQST price to earnings (PE)

For valuing profitable companies with steady earnings

AQST price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

AQST's financial health

Profit margin

Net Income
Profit Margin
AQST's Earnings (EBIT) of -$6.04M... subscribe to Premium to read more.
Interest Coverage Financials
AQST's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Debt to equity
AQST's short-term assets ($42.46M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AQST's long-term liabilities ($138.32M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AQST's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AQST's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

AQST's operating cash flow ($7.01M)... subscribe to Premium to read more.
Debt Coverage Financials

AQST vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B

Aquestive Therapeutics Stock FAQ

What is Aquestive Therapeutics's quote symbol?

(NASDAQ: AQST) Aquestive Therapeutics trades on the NASDAQ under the ticker symbol AQST. Aquestive Therapeutics stock quotes can also be displayed as NASDAQ: AQST.

If you're new to stock investing, here's how to buy Aquestive Therapeutics stock.

What is the 52 week high and low for Aquestive Therapeutics (NASDAQ: AQST)?

(NASDAQ: AQST) Aquestive Therapeutics's 52-week high was $2.95, and its 52-week low was $0.72. It is currently -14.92% from its 52-week high and 248.61% from its 52-week low.

How much is Aquestive Therapeutics stock worth today?

(NASDAQ: AQST) Aquestive Therapeutics currently has 66,767,283 outstanding shares. With Aquestive Therapeutics stock trading at $2.51 per share, the total value of Aquestive Therapeutics stock (market capitalization) is $167.59M.

Aquestive Therapeutics stock was originally listed at a price of $16.05 in Jul 25, 2018. If you had invested in Aquestive Therapeutics stock at $16.05, your return over the last 5 years would have been -84.36%, for an annualized return of -31% (not including any dividends or dividend reinvestments).

How much is Aquestive Therapeutics's stock price per share?

(NASDAQ: AQST) Aquestive Therapeutics stock price per share is $2.51 today (as of Feb 21, 2024).

What is Aquestive Therapeutics's Market Cap?

(NASDAQ: AQST) Aquestive Therapeutics's market cap is $167.59M, as of Feb 22, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Aquestive Therapeutics's market cap is calculated by multiplying AQST's current stock price of $2.51 by AQST's total outstanding shares of 66,767,283.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.